Trisha Dwight

List of Publications by Citations

40 papers	1,554 citations	23 h-index	39 g-index
40 ext. papers	1,798 ext. citations	5.6 avg, IF	3.89 L-index

#	Paper	IF	Citations
40	Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 4440-5	5.6	187
39	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. *Nature Reviews Endocrinology*, **2017**, 13, 233-247	15.2	140
38	Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. *Scientific Reports*, **2016**, 6, 26191	4.9	103
37	Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. *American Journal of Surgical Pathology*, **2013**, 37, 226-33	6.7	102
36	Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. *Scientific Reports*, **2016**, 6, 22477	4.9	94
35	Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1103-8	5.6	87
34	Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. *Genes Chromosomes and Cancer*, **2002**, 35, 74-80	5	76
33	Alternative genetic pathways in parathyroid tumorigenesis. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 3775-80	5.6	75
32	Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. *American Journal of Surgical Pathology*, **2016**, 40, 599-607	6.7	65
31	Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene. *Oncogene*, **2005**, 24, 1467-76	9.2	63
30	Succinate dehydrogenase deficiency is rare in pituitary adenomas. *American Journal of Surgical Pathology*, **2014**, 38, 560-6	6.7	59
29	Alternative Genetic Pathways in Parathyroid Tumorigenesis. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 3775-3780	5.6	59
28	Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. *European Journal of Endocrinology*, **2002**, 147, 313-22	6.5	37
27	structural rearrangements in metastatic pheochromocytomas. *Endocrine-Related Cancer*, **2018**, 25, 1-9	5.7	35
26	A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. *Journal of Medical Genetics*, **2005**, 42, 69-74	5.8	35
25	Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment. *Frontiers in Oncology*, **2018**, 8, 314	5.3	32
24	Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. *Genes Chromosomes and Cancer*, **1999**, 26, 322-8	5	30

23	Bayesian approach to determining penetrance of pathogenic SDH variants. *Journal of Medical Genetics*, **2018**, 55, 729-734	5.8	29
22	Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. *American Journal of Pathology*, **2002**, 161, 1299-306	5.8	28
21	Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. *Endocrine-Related Cancer*, **2014**, 21, 415-26	5.7	27
20	Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 1034-43	5.6	26
19	Characteristic sequence motifs located at the genomic breakpoints of the translocation t(X;18) in synovial sarcomas. *Oncogene*, **2003**, 22, 2215-22	9.2	26
18	Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13. *Clinical Endocrinology*, **2000**, 53, 85-92	3.4	25
17	Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types. *Molecular Genetics and Metabolism Reports*, **2017**, 10, 45-49	1.8	19
16	Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil. *Asian Journal of Andrology*, **2007**, 9, 760-70	2.8	16
15	Analysis of SDHAF3 in familial and sporadic pheochromocytoma and paraganglioma. *BMC Cancer*, **2017**, 17, 497	4.8	15
14	Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 1163-1182	5.6	13
13	Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. *Endocrine Connections*, **2020**, 9, 489-497	3.5	8
12	Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency. *Scientific Data*, **2017**, 4, 170120	8.2	7
11	A rapid method for DNA extraction from fine-needle aspiration biopsies of thyroid tumors, and subsequent RET mutation analysis. *Cancer Detection and Prevention*, **1998**, 22, 544-8		7
10	Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. *Journal of Pathology*, **2017**, 242, 273-283	9.4	6
9	Frequency of codon 1061 and codon 1309 APC mutations in Australian familial adenomatous polyposis patients. *Human Mutation*, **1998**, Suppl 1, S56-7	4.7	6
8	Effectiveness of antidepressants in the treatment of major depressive disorder in Latin America. *International Journal of Psychiatry in Clinical Practice*, **2007**, 11, 129-39	2.4	6
7	Metabolomics in the Diagnosis of Pheochromocytoma and Paraganglioma. *Hormone and Metabolic Research*, **2019**, 51, 443-450	3.1	5
6	Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e350-e364	5.6	2

5	Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors **2005**, 26, 141		1
4	Impact of molecular cytogenetics on localization and identification of cancer-related genes in endocrine tumor development. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2003**, 10, 176-185		1
3	Parathyroid tumorigenesis in association with primary hyperparathyroidism. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2002**, 9, 51-60		1
2	Functional significance of germline EPAS1 variants. *Endocrine-Related Cancer*, **2021**, 28, 97-109	5.7	1
1	Measuring Tumor Succinate and Fumarate to Resolve Pathogenicity of an SDHA Variant. *Clinical Chemistry*, **2021**, 67, 696-699	5.5	